News

Positive Topline Results Announced for ACCESS Studies for Aleniglipron (Oral GLP-1 RA)

Congratulations to the Structure Therapeutics team for announcing positive topline data from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist. Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee and Senior Scientific Advisor at Velocity, is quoted in the press release: “The weight-lowering data from these ACCESS studies, without any evidence … Read more

Henrik Watz, MD, PhD, Authors Results for the First Clinical Trial of Glasmacinal (EP395) in COPD Patients

Henrik Watz, MD, PhD, is the chief investigator and author of trial results for EpiEndo’s clinical trial of glasmacinal (EP395). Results indicated that glasmacinal reduced neutrophilic inflammation in COPD patients without any detectable impact on the lung microbiome, supporting preclinical findings of reduced antimicrobial resistance potential. Dr. Watz in the accompanying press release: “The data … Read more

Stanley Hsia, MD, Presents Phase 2 Trial Results for Mazdutide (GLP-1/Glucagon Dual Agonist)

At ObesityWeek in Atlanta, Stanley Hsia, MD, presented results from a Phase 2 Eli Lilly/Innovent Biologics study of mazdutide, a once-weekly injectable GLP-1/glucagon dual agonist. The study demonstrated dose-dependent weight loss. Dr. Hsia: “All of these mazdutide treatment curves did not seem to plateau, suggesting that had we continued treatment beyond 48 weeks, greater degrees … Read more

Velocity Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer

Velocity Clinical Research, the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world’s leading contract research organizations (CROs), where he held senior leadership roles driving growth strategies and global business development. This appointment represents a pivotal … Read more

An Interview with Gerald Cephas, MD, on Advancing Psychiatric Research and Promoting Equity in Care

A research career wasn’t part of Gerald Cephas, MD’s original plan. He trained in general surgery, intending to specialize in pediatrics, but a health setback during residency changed his course. “Toward the end of residency, I got sick,” he explains. “So, long story short, research presented itself as a Plan B, and I’ve been on … Read more

Op-ed: How Data is Driving GenAI Solutions in Clinical Trials

By Tyler Beasley, Head of Business Intelligence at Velocity Clinical Research The future of successful clinical trials will be written in data. Generative AI (GenAI) is already transforming how Sponsors, CROs, and sites approach research, but the real impact will come when AI is deployed with scale and smart infrastructure. That’s where Velocity’s model gives … Read more

Winning Through Scale: How We’re Building Toward $500M Revenue

Investors care about many things, but when they say scale, they mean revenue. Two times, five times, ten times… whatever the directive, it’s centered on revenue growth. For leadership teams, the focus on revenue milestones is more nuanced. Each one matters to investors, yes. But each also marks a strategic shift. The decisions, disciplines, and … Read more

Potential Breakthrough to Preserve Lean Muscle Mass During GLP-1-Induced Weight Loss

The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution. The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean … Read more

Julio Rosenstock, MD Lead Author of Phase 2 Trial Results Evaluating Orforglipron Published in Diabetes, Obesity and Metabolism

Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism. The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in participants with type 2 diabetes (T2D). These results support orforglipron’s potential … Read more